Shanghai Raas Blood Products Co., Ltd. Class ASZSE: 002252

Shanghai RAAS Blood Products: Q1 2026 saw revenue and profit decline sharply year-over-year, but sequential improvement emerged

· Issued by Shanghai Raas Blood Products Co., Ltd. Class A

Q1 2026 revenue fell 24.75% year-over-year to ¥1.51 billion, with net profit down 43.85% due to VAT policy changes, market competition, and strategic business adjustments. Sequential improvement was seen from Q4 2025 as transformation efforts began to show results.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Shanghai Raas Blood Products Co., Ltd. Class A

All Shanghai Raas Blood Products Co., Ltd. Class A news releases